Byondis logo

Byondis jobs and careers

NIJMEGEN, Netherlands

About Byondis

With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.

Founded in 2010 by Jacques Lemmens.

Founded
2010
Employees
350
Headquarters
NIJMEGEN

Leadership

The top of Byondis's org chart, with how many people report into each leader.

WDPhoto of Wim Dokter

Wim Dokter

Chief Scientific Officer

57 reports

ALPhoto of Aad van de Leur

Aad van de Leur

COO

33 reports

RS

Ronald Smulders

Senior Director Quality Assurance

17 reports

NKPhoto of Norbert Koper

Norbert Koper

Vice President Clinical Development

4 reports

IGPhoto of Ivo Grgic

Ivo Grgic

Senior Director Business Development & Licensing

1 report

MGPhoto of Marieke van Gent

Marieke van Gent

Vice President Intellectual Property

1 report

SGPhoto of Suzanne van Gerwen

Suzanne van Gerwen

Director Business Development

BIPhoto of Benno Ingelse

Benno Ingelse

Senior Director Bioanalysis & Protein Interaction

16 reports

BKPhoto of Bas Kokke

Bas Kokke

Principal Scientist DSP

7 reports

MLPhoto of Miranda van der Lee

Miranda van der Lee

Senior Director In Vitro Pharmacology

7 reports

PBPhoto of Patrick Beusker

Patrick Beusker

Senior Director Medicinal & Protein Chemistry

5 reports

AMPhoto of Alyson MacInnes

Alyson MacInnes

Director Biomarker Discovery And Development

4 reports

RU

Ruud Ubink

Senior Director DMPK

2 reports

PGPhoto of Patrick Groothuis

Patrick Groothuis

Principal Scientist, In Vivo Pharmacology, Toxicology & DMPK

1 report

TA

Taiwo Ajayi

Head Of Biometrics

1 report